Securing the exemption from CVA charges in the new bank capital rules within the EU was a crucial element of the EACT's campaign to ensure that OTC derivatives continued to be available to corporates for risk management and that the pricing remained competitive. Policy in the United States towards the CVA exemption has been and remains a concern to the EACT. In March, the EACT Chairman wrote to Mr Daniel Pinto, Co-CEO Corporate & Investment at JP Morgan, to seek clarity on the position of the bank with respect to the EU CVA exemption and to ask what action has been undertaken by the bank in the last six months. In his response, Mr. Pinto stated that JP Morgan has not called for a repeal of the CVA exemption for corporate end users, yet also expressed concern that the approach by the regulators was not globally consistent and, as such, creates competitive inequalities.
EACT Board Member, Guillermo De La Fuente has been selected as member of the European Banking Authority (EBA)'s Stakeholder Group.
View MoreThis year, we received circa 250 answers from Group Treasurers of the largest international companies across Europe. We are delighted to share the results with you.
View MoreThe Italian association (AITI) are pleased to share a survey on sustainable supply chain finance. All EACT members are invited to take part.
View MoreThe EACT Board would like to personally thank all our delegates and sponsors in attendance at last week's EACT Summit.
View MoreEACT representatives were delighted to announce the three winners of this year's EACT Award during a ceremony at the recent Summit in Brussels.
View More